Drug intelligence / Profile preview

Bristol-Myers Squibb TYK2 JH2 compound 4h

Development stage: Unknown
Lead developer: Bristol Myers Squibb

Overview

Bristol-Myers Squibb TYK2 JH2 compound 4h: sourced facts only. name: "The current SAR study resulted in the identification of 4h as a potent and selective TYK2 JH2 inhibitor with distinct structural differences from 1a." [PMID:37315697]; target: "The current SAR study resulted in the identification of 4h as a potent and selective TYK2 JH2 inhibitor with distinct structural differences from 1a." [PMID:37315697]; developer: "Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States. Electronic address: [email protected]." [PMID:37315697]

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on Bristol-Myers Squibb TYK2 JH2 compound 4h.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bristol-Myers Squibb TYK2 JH2 compound 4h.